Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region

被引:0
作者
Ekushov, Vasily E. [1 ]
Totmenin, Alexei, V [1 ]
Gotfrid, Ludmila G. [1 ]
Halikov, Maksim R. [1 ]
Minikhanova, Vitalla-Victoria V. [2 ]
Skudarnov, Sergey E. [2 ]
Ostapova, Tatyana S. [2 ]
Gashnikova, Natalya M. [1 ]
机构
[1] Vector State Res Ctr Virol & Biotechnol, Rospotrebnadzor, Koltsovo, Russia
[2] Krasnoyarsk Reg Ctr Prevent & Control AIDS, Krasnoyarsk, Russia
关键词
HCV; Hepatitis C subtypes; RASs; NS5A; DAAs; genetic polymorphism; DACLATASVIR PLUS SOFOSBUVIR; DIRECT-ACTING ANTIVIRALS; GENOTYPE; 1-6; JAPANESE PATIENTS; HCV INFECTION; VARIANTS; 1B; SUBSTITUTIONS; GRAZOPREVIR; COMBINATION;
D O I
10.18470/1992-1098-2024-1-4
中图分类号
Q14 [生态学(生物生态学)];
学科分类号
071012 ; 0713 ;
摘要
To research the molecular genetic characteristics of the HCV population circulating among HIV -infected residents of the Krasnoyarsk Territory, including analysis of resistance -associated mutations to NS5A inhibitors. Total RNA was isolated from 94 blood plasma samples from HIV/HCVinfected residents of the region and the nucleotide sequences of the Core/E1 gene and NS5A gene regions were obtained and deciphered, which were used for genotyping and searching for resistance mutations. In the HCV samples studied, the circulation of five virus subtypes was recorded: 1b (47,9 %), 3a (37,2 %), 1a (10,6 %), 2a (3,2 %) and 2k (1,1 %). Phylogenetic analysis of HCVs revealed partial clustering within subtypes 1a and 3a on a territorial basis. HCV subtypes 1b, 2a and 2k were grouped with other HCVs previously isolated in Russia, Armenia and Kyrgyzstan. Among the HCVs studied, no clusters were found that were common to HIV -infected individuals with the same route of infection. Among patients who had no experience of taking DAAs, HCV resistance mutations in the NS5A region were found in 42,3 % of cases for those infected with subtype 3a virus and in 75,6 % of cases for those infected with HCV subtype 1b. The analysis of the diversity and occurrence of mutations of HCV drug resistance to direct antiviral drugs is extremely important for the development of tactics for effective treatment of CHC. The high prevalence of polymorphic mutations that affect sensitivity to DAAs indicates the relevance of introducing HCV resistance analysis into clinical practice.
引用
收藏
页码:47 / 59
页数:189
相关论文
共 59 条
[1]   Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals [J].
Azeredo Cabral, Bianca Catarina ;
Ramos, Juliene Antonio ;
de Melo Silveira, Amanda Laryssa ;
dos Santos Nascimento, Erica Ramos ;
Ferreira, Selma Baia ;
Moraes Coelho, Henrique Sergio ;
Moura-Neto, Rodrigo Soares ;
Villela-Nogueira, Cristiane Alves ;
Hoffmann, Luisa ;
Silva, Rosane .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 115 :171-177
[2]   Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment [J].
Bartels, Doug J. ;
Sullivan, James C. ;
Zhang, Eileen Z. ;
Tigges, Ann M. ;
Dorrian, Jennifer L. ;
De Meyer, Sandra ;
Takemoto, Darin ;
Dondero, Elizabeth ;
Kwong, Ann D. ;
Picchio, Gaston ;
Kieffer, Tara L. .
JOURNAL OF VIROLOGY, 2013, 87 (03) :1544-1553
[3]   Chronic hepatitis C: This and the new era of treatment [J].
Bertino, Gaetano ;
Ardiri, Annalisa ;
Proiti, Maria ;
Rigano, Giuseppe ;
Frazzetto, Evelise ;
Demma, Shirin ;
Ruggeri, Maria Irene ;
Scuderi, Laura ;
Malaguarnera, Giulia ;
Bertino, Nicoletta ;
Rapisarda, Venerando ;
Di Carlo, Isidoro ;
Toro, Adriana ;
Salomone, Federico ;
Malaguarnera, Mariano ;
Bertino, Emanuele ;
Malaguarnera, Michele .
WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (02) :92-106
[4]   Global prevalence of pre-existing HCV variants resistant to directacting antiviral agents (DAAs): mining the GenBank HCV genome data [J].
Chen, Zhi-wei ;
Li, Hu ;
Ren, Hong ;
Hu, Peng .
SCIENTIFIC REPORTS, 2016, 6
[5]   Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis [J].
Curry, M. P. ;
O'Leary, J. G. ;
Bzowej, N. ;
Muir, A. J. ;
Korenblat, K. M. ;
Fenkel, J. M. ;
Reddy, K. R. ;
Lawitz, E. ;
Flamm, S. L. ;
Schiano, T. ;
Teperman, L. ;
Fontana, R. ;
Schiff, E. ;
Fried, M. ;
Doehle, B. ;
An, D. ;
McNally, J. ;
Osinusi, A. ;
Brainard, D. M. ;
McHutchison, J. G. ;
Brown, R. S., Jr. ;
Charlton, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2618-2628
[6]   Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients [J].
Dietz, Julia ;
Susser, Simone ;
Berkowski, Caterina ;
Perner, Dany ;
Zeuzem, Stefan ;
Sarrazin, Christoph .
PLOS ONE, 2015, 10 (08)
[7]   Hepatitis C virus proteins [J].
Dubuisson, Jean .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) :2406-2415
[8]   EASL Recommendations on Treatment of Hepatitis C 2018 [J].
Pawlotsky J.-M. ;
Negro F. ;
Aghemo A. ;
Berenguer M. ;
Dalgard O. ;
Dusheiko G. ;
Marra F. ;
Puoti M. ;
Wedemeyer H. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511
[9]   Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor [J].
Fourati, S. ;
Guedj, J. ;
Chevaliez, S. ;
Nguyen, T. H. T. ;
Roudot-Thoraval, F. ;
Ruiz, I. ;
Soulier, A. ;
Scoazec, G. ;
Varaut, A. ;
Poiteau, L. ;
Francois, M. ;
Mallat, A. ;
Hezode, C. ;
Pawlotsky, J. -M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) :665-673
[10]   Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants [J].
Gottwein, Judith M. ;
Pham, Long V. ;
Mikkelsen, Lotte S. ;
Ghanem, Lubna ;
Ramirez, Santseharay ;
Scheel, Troels K. H. ;
Carlsen, Thomas H. R. ;
Bukh, Jens .
GASTROENTEROLOGY, 2018, 154 (05) :1435-1448